Univariate and multivariable overall survival analysis of 75 patients with blast phase myeloproliferative neoplasms
| Variables . | Univariate analysis . | Multivariable analysis . | ||||
|---|---|---|---|---|---|---|
| HR . | 95% CI . | P . | HR . | 95% CI . | P . | |
| Age, y | .05 | |||||
| Age >65 y | 1.5 | 0.9-2.4 | .09 | |||
| Male sex | 1.3 | 0.8-2.1 | .3 | |||
| Transfusion-dependent; “N” evaluable = 71 (95%) | .14 | 0.8-2.4 | .1 | |||
| Hemoglobin, g/dL; “N” evaluable = 69 (92%) | .5 | |||||
| Platelets, × 109/L; “N” evaluable = 69 (92%) | .4 | |||||
| Platelets < 100 × 109/L; “N” evaluable = 69 (92%) | 1.5 | 0.9-2.5 | .09 | |||
| Leukocytes, × 109/L; “N” evaluable = 69 (92%) | .2 | |||||
| Leukocytes > 25 × 109/L; “N” evaluable = 69 (92%) | 1.4 | 0.8-2.3 | .2 | |||
| Circulating blasts %; “N” evaluable = 70 (93%) | .8 | |||||
| Circulating blasts ≥20%; “N” evaluable = 70 (93%) | 0.9 | 0.6-1.7 | .9 | |||
| BM blasts; “N” evaluable = 61 (81%) | .8 | |||||
| BM blasts ≥20%; “N” evaluable = 61 (81%) | 1.0 | 0.5-2.1 | .9 | |||
| MPN variant | ||||||
| Post-PMF AML | 0.9 | 0.5-1.7 | .8 | |||
| Post-ET AML | 0.9 | 0.4-1.7 | .7 | |||
| Post-PV AML (reference) | — | — | — | |||
| Karyotype; “N” evaluable = 62 (83%) | ||||||
| Very high-risk karyotype | 1.8 | 0.9-3.6 | .07 | |||
| Unfavorable karyotype | 1.2 | 0.6-2.3 | .6 | |||
| Favorable karyotype (reference) | — | — | — | |||
| RUNX1 mutated | 2.1 | 1.1-3.8 | .02 | 2.9 | 1.5-5.5 | <.001 |
| PTPN11 mutated | 3.0 | 1.2-7.0 | .01 | |||
| Received transplant or achieved CR/CRi | 0.3 | 0.2-0.6 | <.001 | 0.3 | 0.2-0.5 | <.001 |
| Variables . | Univariate analysis . | Multivariable analysis . | ||||
|---|---|---|---|---|---|---|
| HR . | 95% CI . | P . | HR . | 95% CI . | P . | |
| Age, y | .05 | |||||
| Age >65 y | 1.5 | 0.9-2.4 | .09 | |||
| Male sex | 1.3 | 0.8-2.1 | .3 | |||
| Transfusion-dependent; “N” evaluable = 71 (95%) | .14 | 0.8-2.4 | .1 | |||
| Hemoglobin, g/dL; “N” evaluable = 69 (92%) | .5 | |||||
| Platelets, × 109/L; “N” evaluable = 69 (92%) | .4 | |||||
| Platelets < 100 × 109/L; “N” evaluable = 69 (92%) | 1.5 | 0.9-2.5 | .09 | |||
| Leukocytes, × 109/L; “N” evaluable = 69 (92%) | .2 | |||||
| Leukocytes > 25 × 109/L; “N” evaluable = 69 (92%) | 1.4 | 0.8-2.3 | .2 | |||
| Circulating blasts %; “N” evaluable = 70 (93%) | .8 | |||||
| Circulating blasts ≥20%; “N” evaluable = 70 (93%) | 0.9 | 0.6-1.7 | .9 | |||
| BM blasts; “N” evaluable = 61 (81%) | .8 | |||||
| BM blasts ≥20%; “N” evaluable = 61 (81%) | 1.0 | 0.5-2.1 | .9 | |||
| MPN variant | ||||||
| Post-PMF AML | 0.9 | 0.5-1.7 | .8 | |||
| Post-ET AML | 0.9 | 0.4-1.7 | .7 | |||
| Post-PV AML (reference) | — | — | — | |||
| Karyotype; “N” evaluable = 62 (83%) | ||||||
| Very high-risk karyotype | 1.8 | 0.9-3.6 | .07 | |||
| Unfavorable karyotype | 1.2 | 0.6-2.3 | .6 | |||
| Favorable karyotype (reference) | — | — | — | |||
| RUNX1 mutated | 2.1 | 1.1-3.8 | .02 | 2.9 | 1.5-5.5 | <.001 |
| PTPN11 mutated | 3.0 | 1.2-7.0 | .01 | |||
| Received transplant or achieved CR/CRi | 0.3 | 0.2-0.6 | <.001 | 0.3 | 0.2-0.5 | <.001 |
Bold indicates significant values.